Listen to a replay of our Q4 2019 Earnings Call

Click Here

Adaptimmune Announces SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Read More

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Read More

Adaptimmune Appoints Elliot Norry as CMO and Makes Changes to R&D Leadership

Read More

You can find new videos about our SPEAR T-cells

Learn More